Bioprocessing & Pharma

What did we learn from Big Pharma’s Q2 results?

By Ayla Ellison , Fraiser Kansteiner , James Waldron · 8/21/2026

Fierce editors break down Big Pharma’s second-quarter results, from AI and new leadership to the oral GLP-1 race and potential new blockbusters.

This is a preview. Read the complete article on Fierce Pharma.